CRO Solutions, Inc. Announces Opening of New Division – VxP Pharma Services, Inc.

INDIANAPOLIS, Indiana – CRO Solutions, Inc. announced the launch of VxP Pharma, Inc.- a wholly owned subsidiary of CRO Solutions, Inc. VxP Pharma is comprised of the combined services of the independently owned and operated "niche" CROs of parent company - CRO Solutions, Inc. VxP Pharma will offer pharmaceutical development services, as well as technical support, for the development and production of pharmaceuticals, diagnostics, and drug/device combination products from Discovery through Phase IIb.


The majority of VxP Pharma's Labs are located in the United States, although VxP also has facilities in Europe and Asia.  All VxP sites have been fully audited by CRO Solutions/VxP Pharma, as well as by global pharmaceutical and biotechnology clients. Most sites have also been audited by the US FDA as well as other international regulatory agencies.

VxP Pharma CEO – Raymond E Peck says: "Pharmaceutical and biotech research scientists throughout the industry tell us that they prefer to work with smaller, focused, Contract Research Organizations (CROs), rather than with the huge multinational 'one-size-fits-all' CROs. For these people, VxP Pharma is a perfect fit because we offer a single point of contact, as well as the confidence that, if you work with VxP, you are working with a state-of-the-art lab that has been subject to a complete audit, including, in most cases, an audit by the US FDA. Because VxP consists of smaller, independently owned and operated facilities who focus on only one area of drug development, our drug development clients get all the advantages of working directly with a specialist "niche" CRO, including being able to work with some of the best subject matter experts in the industry."

VxP Pharma will operate as a full service CRO offering drug development services from Discovery through Phase llb. VxP is headquartered in Indianapolis, Indiana.  To find out more, please visit: www.vxppharma.com or call at 317-759-2299.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.